Hanjin Up 29.95% to Limit-Up: Share-Cancellation Reports Came After the Close
With KOSPI up 4.39%, Hanjin, Jin Air and Samik Pharm all closed at the 30% daily limit. Only Hanjin has a filing behind the move, and even its coverage appeared after the market closed.

Basis: 2026-11-10 21:04 KST. Closing prices and percentage moves are regular-session closes; index figures are as of 20:15.
Seoul — KOSPI rose 4.39% to 5,239.13 and KOSDAQ (tech- and small-cap-heavy market) rose 4.48% to 667.61 on November 10. On that rebound day Hanjin, Jin Air and Samik Pharm each closed at the 30% daily limit (상한가). Hanjin has a share-cancellation filing, but every report on it appeared after the close. Jin Air had oil-price and low-cost-carrier (LCC) merger reports behind it. Samik Pharm filed nothing.
Selection: three stocks covered here that closed at the daily limit (+29.9% or more, regular-session close). One has its reason confirmed by a filing (Hanjin); two are confirmed by news reports only (Jin Air, Samik Pharm).
At a glance
| Stock | Why it rose | Nature | Evidence | Heat | What to check next |
|---|---|---|---|---|---|
| Hanjin (002320) 22,300 won +29.95% Turnover 50.5bn won |
Decision to cancel 478,401 treasury shares (3.07% of shares outstanding) | Substantive, one-off | Filing confirmed | 1/4 caution | Whether the filing came during trading; turnover next session |
| Samik Pharm (014950) 8,330 won +29.95% Turnover 20.4bn won |
Alopecia-drug report and a pharma rebound coincided. No company filing | Expectation | Reports only | 0/4 normal | Any company filing or comment; who made the "model drug" designation |
| Jin Air (272450) 7,990 won +29.92% Turnover 79.4bn won |
Reports of an oil-price drop and LCC three-way merger hopes | Expectation | Reports only | 3/4 strong overheating | Merger registration filing and the Dec. 17 shareholder meeting |
Hanjin (002320): a share-cancellation decision, but the coverage came after the close

Hanjin rose 29.95% to 22,300 won, and the likeliest cause is the share-cancellation decision filed the same day. Every report on it appeared at 6:01 p.m. or later, and the time of the filing itself is not known. The filing alone cannot fully explain a move during the session.
According to DART (Korea's official disclosure system), Hanjin filed a share-cancellation decision on November 10. Digital Times reported that the board resolved to cancel 478,401 common shares, about 20 billion won at book value. Weekly Hankook said this is 3.07% of shares outstanding and all of the treasury stock. A 3% cancellation looks small next to a 30% jump. Separately, Jangguem Merchant Marine filed a short-form large-shareholding report on the same day and a corrected one on November 5; the stake size cannot be read from the titles. Reports on a shareholder battle at Hanjin Kal (Gongyu Gyeongje Shinmun, Chosun Ilbo) also ran that day, but the titles do not show a direct link to Hanjin.
Overheating check Overheating signals are 1/4 (caution). Volume was 30.1 times the 20-day average, the price is 29.7% above its 20-day line, and RSI is 67.8. It sits mid-range (49%) of its 52-week range, 19.7% below the 52-week high. Fundamentals pass 2 of 6 checks (positive free cash flow and revenue growth of 16.6% passed; loss-making and the debt test did not). Limit-up buy orders stood at 96,862 shares with no sell orders. Turnover of 50.5 billion won is 14.6% of the 346.1 billion won market cap, which may be short-term overheating. The filing is positive in nature (shareholder return).
Investors split. Foreigners sold a net 69,554 shares and institutions 12,495, while individuals bought a net 96,555. Hanjin also rose 17.93% on November 3 and fell 16.68% the next day. Two things to check: whether the filing came during trading hours, and whether turnover holds in the next session.
Samik Pharm (014950): no filing explains the limit-up; an alopecia-drug report and a pharma rebound coincided

Samik Pharm rose 29.95% to 8,330 won, and the company has filed nothing in the past seven days that explains it. The reports point to alopecia-drug news and a pharma rebound. Data Investment reported at 10:26 a.m. under the headline "Baricitinib shows 4+ years of effect in severe alopecia areata... Samik Pharm up 9% on 'model drug' designation." Newspaper Uisyak (Medical News) said the KOSDAQ pharma index rebounded 2.66%. The headline does not say who made the "model drug" designation or how it relates to Samik Pharm. Geumgang Ilbo ran the headline "Samik Pharm stock at limit-up... why?", which shows the cause was unclear.
The stock had fallen steadily from its October 6 close of 8,360 won and rose 37.5% over the last two days, almost back to that level (-0.4% versus October 6). It remains 60.2% below its 52-week high. Foreigners bought a net 205,318 shares after selling 107,172 the day before, and individuals sold a net 214,957. Hana Securities said on June 24 that first-quarter revenue was 15.5 billion won (+10.4% year on year) and operating profit 0.93 billion won (-8.5%). That is a quarterly year-on-year figure; the 5.2% revenue growth in the check below uses a different basis.
Overheating check Overheating signals are 0/4 (normal). RSI is 49.3, the price is 14.8% above its 20-day line, and volume was 1.4 times the 20-day average. Five-day gain is 24.0%. It is 7.3% below its 200-day line, at 26% of its 52-week range. Fundamentals pass 2 of 6 checks (the debt test and revenue growth passed; loss-making and negative free cash flow did not). Limit-up buy orders stood at 291,646 shares with no sell orders. Turnover of 20.4 billion won is 24.3% of the 84.0 billion won market cap, which may be short-term overheating. Two things to check: whether the company files or comments on baricitinib, and whether foreign buying and turnover continue next session.
Jin Air (272450): oil-price drop and LCC merger hopes, while the merger timetable slips

Jin Air rose 29.92% to 7,990 won; reports attribute it to a sharp fall in international oil prices lifting airline stocks and to hopes for the Air Busan–Air Seoul combination. Geumgang Ilbo and Daehan Daily reported that airline stocks surged on the oil drop, with Korean Air, Jin Air and others at the limit. A Korean Air limit-up headline means this was not only a Jin Air story. Moneystorm cited "growing synergy expectations from the Air Busan–Air Seoul integration" and Wide Economy cited "positive views on the three-LCC merger." Eugene Investment & Securities said in an October 30 report that high oil prices would weigh through the fourth quarter, which shows oil is a cost variable for the company.
There is contrary news. Newdaily and Topdaily reported that the Ministry of Land's merger approval was delayed, Jin Air has not filed its registration statement, and the shareholder meeting set for December 17 may slip. Newstomato reported that Air Busan and Air Seoul unions asked Jin Air to guarantee seniority. DART shows a preliminary operating results disclosure and IR notices on November 6 and a CEO change notice on November 3, but no report linked them to the limit-up, and their figures are not covered here. Institutions bought a net 644,115 shares and foreigners 288,377, while individuals sold a net 889,938.
Overheating check Overheating signals are 3/4 (strong overheating). Volume was 41.2 times the 20-day average, the price is 36.4% above its 20-day line, and the five-day gain is 42.9% (RSI 77.3). It closed at the top (100%) of its 52-week range and is 31.8% above its 200-day line. It passes all 3 checkable fundamentals (profitable, positive free cash flow, ROE of 10% or more). Limit-up buy orders stood at 354,339 shares with no sell orders. Turnover of 79.4 billion won is 19.0% of the 417.1 billion won market cap, which may be short-term overheating. Two things to check: whether the merger registration statement is filed and the December 17 meeting holds, and whether oil keeps the day's drop.
FAQ
Q. Why did they rise? Hanjin: a share-cancellation decision (3.07% of shares). Jin Air: reports of an oil-price drop and LCC merger hopes. Samik Pharm: no company filing, only an alopecia-drug report and a pharma-index rebound.
Q. Which filing is the basis? Hanjin's November 10 share-cancellation decision (DART receipt no. 20261110800680). Jin Air and Samik Pharm have no filing that directly explains the rise.
Q. What should I check next? Jin Air's merger meeting is reported for December 17, with possible delay. Hanjin's cancellation date should be read in the filing itself.
What happened to stocks we covered before
All three stocks judged as filing-confirmed rose afterward, and all three judged as reports-only fell. The sample is small. Two stocks whose earlier verdict is missing are shown as unverified rather than guessed.
| Stock | Article date | Earlier basis | Move since (Nov 10 close) |
|---|---|---|---|
| Hanjin Kal | 11/3 | Filing | +35.0% |
| Proteina | 11/5 | Filing | +13.9% |
| Mercury | 11/9 | Filing | +2.0% |
| Pharmicell | 11/9 | Reports | -4.7% |
| Daedong Metal | 11/9 | Reports | -2.9% |
| Kleannara | 11/6 | Reports | -8.4% |
| Duksung | 11/6 | Unverified | -10.9% |
| Elice | 11/6 | Unverified | -0.1% |
FAQ
Why did Hanjin stock go up?
Decision to cancel 478,401 treasury shares (3.07% of shares outstanding). Evidence: Filing confirmed. What to check next: 1/4 caution.
Why did Samik Pharm stock go up?
Alopecia-drug report and a pharma rebound coincided. No company filing. Evidence: Reports only. What to check next: 0/4 normal.
Why did Jin Air stock go up?
Reports of an oil-price drop and LCC three-way merger hopes. Evidence: Reports only. What to check next: 3/4 strong overheating.